{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"84"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"66"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"100"}],"units":"Participants"}],"description":"Number of participants who had at least 2\\*10\\^6 CD34+ cells/kg collected by apheresis during both the first and the second courses of treatment together.","groups":[{"description":"Participants with non-Hodgkin's lymphoma (NHL) were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 7 aphereses or until ≥ 2\\*10\\^6 CD34+ cells/kg were collected.","id":"OG000","title":"Non-Hodgkin's Lymphoma"},{"description":"Participants with Hodgkin's disease (HD) were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 7 aphereses or until ≥ 2\\*10\\^6 CD34+ cells/kg were collected.","id":"OG001","title":"Hodgkin's Disease"},{"description":"Participants with multiple myeloma (MM) were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 7 aphereses or until ≥ 2\\*10\\^6 CD34+ cells/kg were collected.","id":"OG002","title":"Multiple Myeloma"},{"description":"Participants with 'other' cancers (desmoplastic small round cell tumor, acute myeloid leukemia, and testicular cancer) were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 7 aphereses or until ≥ 2\\*10\\^6 CD34+ cells/kg were collected.","id":"OG003","title":"Other Cancers"},{"id":"OG004","title":"All Patients"}],"paramType":"NUMBER","populationDescription":"Participants who received one course or two courses of plerixafor. Four NHL participants and 3 HD participants had two courses of plerixafor and the sum of CD34+ cells/kg collected in both courses is included.","reportingStatus":"POSTED","timeFrame":"Day 5 up to Month 6 (up to 7 aphereses in each course of treatment)","title":"Number of Participants Who Achieved ≥2*10^6 CD34+ Cells/kg Collected During Both Courses of Treatment With Plerixafor and G-CSF","type":"SECONDARY","unitOfMeasure":"Participants"}